At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
HSK3486 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating HSK3486, Moxifloxacin Hydrochloride, and 1 other intervention for Anesthesia; Adverse Effect and Cardiac Arrhythmia. Completed, enrolled 48 participants across 1 site.
Detailed Summary
To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia; Adverse Effect, Cardiac Arrhythmia
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
Enrollment StartApr 2024
Primary CompletionMay 2024
Study CompletionNov 2024
First PostedJan 2025
TodayJul 2026
First PostedJan 27, 2025
Enrollment StartApr 9, 2024
Primary CompletionMay 19, 2024
Study CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 1.4 years ago
Interventions
HSK3486drug
Study Drug
Moxifloxacin Hydrochloridedrug
Positive Control
Placebodrug
Negative Control